Last reviewed · How we verify
Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan is a Monoclonal antibody (ramucirumab) + chemotherapy combination Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 3 development for Advanced gastric cancer or gastroesophageal junction cancer (in combination with chemotherapy), Non-small cell lung cancer (in combination with chemotherapy), Colorectal cancer (in combination with chemotherapy).
This is a combination regimen pairing ramucirumab (a VEGF receptor 2 inhibitor) with chemotherapy agents (paclitaxel, docetaxel, or irinotecan) to block tumor angiogenesis while simultaneously attacking cancer cells.
This is a combination regimen pairing ramucirumab (a VEGF receptor 2 inhibitor) with chemotherapy agents (paclitaxel, docetaxel, or irinotecan) to block tumor angiogenesis while simultaneously attacking cancer cells. Used for Advanced gastric cancer or gastroesophageal junction cancer (in combination with chemotherapy), Non-small cell lung cancer (in combination with chemotherapy), Colorectal cancer (in combination with chemotherapy).
At a glance
| Generic name | Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Monoclonal antibody (ramucirumab) + chemotherapy combination |
| Target | VEGF receptor 2 (VEGFR2); tubulin (taxanes) / topoisomerase I (irinotecan) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ramucirumab is a monoclonal antibody that binds to VEGF receptor 2 (VEGFR2) on endothelial cells, inhibiting tumor neovascularization and reducing blood supply to tumors. The chemotherapy components (paclitaxel, docetaxel, or irinotecan) work through distinct mechanisms—taxanes stabilize microtubules while irinotecan inhibits topoisomerase I—to directly kill rapidly dividing cancer cells. The combination leverages anti-angiogenic and cytotoxic mechanisms synergistically.
Approved indications
- Advanced gastric cancer or gastroesophageal junction cancer (in combination with chemotherapy)
- Non-small cell lung cancer (in combination with chemotherapy)
- Colorectal cancer (in combination with chemotherapy)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Neuropathy (peripheral)
- Hypertension
- Fatigue
- Nausea/vomiting
- Diarrhea
Key clinical trials
- AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (PHASE3)
- SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen (PHASE3)
- Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan CI brief — competitive landscape report
- Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI
Frequently asked questions about Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
What is Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan?
How does Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan work?
What is Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan used for?
Who makes Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan?
What drug class is Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan in?
What development phase is Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan in?
What are the side effects of Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan?
What does Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan target?
Related
- Drug class: All Monoclonal antibody (ramucirumab) + chemotherapy combination drugs
- Target: All drugs targeting VEGF receptor 2 (VEGFR2); tubulin (taxanes) / topoisomerase I (irinotecan)
- Manufacturer: Jiangsu HengRui Medicine Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced gastric cancer or gastroesophageal junction cancer (in combination with chemotherapy)
- Indication: Drugs for Non-small cell lung cancer (in combination with chemotherapy)
- Indication: Drugs for Colorectal cancer (in combination with chemotherapy)
- Compare: Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan vs similar drugs
- Pricing: Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan cost, discount & access